Trial Profile
A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Abicipar pegol (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Allergan
- 08 Aug 2014 New trial record